The populations of wealthy western nations are getting older and sicker, while emerging countries are demanding better ...

The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have been saved, if only abandoned discoveries had been given another chance.

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.

Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 34.3% in premarket trading. The once-daily oral drug ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

In a previous clinical trial, Summit's cancer drug ivonescimab showed it was more effective than Keytruda. The excitement propelled Summit's stock to a valuation that at one point reached $27 billion.

SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck ...